Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary

被引：11

作者：

Anderson, Kenneth

Ismaila, Nofisat

Kyle, Robert A.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Amer Soc Clin Oncol, Alexandria, VA USA

[3] Mayo Clin, Rochester, MN USA

来源：

JOURNAL OF ONCOLOGY PRACTICE | 2018年 / 14卷 / 04期

关键词：

D O I：

10.1200/JOP.17.00013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：266 / +

页数：5

共 2 条

[1] Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update [J].

Anderson, Kenneth ;

Ismaila, Nofisat ;

Flynn, Patrick J. ;

Halabi, Susan ;

Jagannath, Sundar ;

Ogaily, Mohammed S. ;

Omel, Jim ;

Raje, Noopur ;

Roodman, G. David ;

Yee, Gary C. ;

Kyle, Robert A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) :812-+

[2] American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma [J].

Kyle, Robert A. ;

Yee, Gary C. ;

Somerfield, Mark R. ;

Flynn, Patrick J. ;

Halabi, Susan ;

Jagannath, Sundar ;

Orlowski, Robert Z. ;

Roodman, David G. ;

Twilde, Patricia ;

Anderson, Kenneth .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) :2464-2472

← 1 →